This Article  • References  • Full text PDF  • Reply to article  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Social Bookmarking   What's this?

George J. Brewer, MD; Robert D. Dick; Vilma Yuzbasiyan-Gurkin, PhD; Roberta Tankanow, MS; Anne B. Young, MD; Karen J. Kluin, MS

Arch Neurol. 1991;48(1):42-47.

Abstract
• Patients with Wilson's disease who present with acute neurological symptoms often become clinically worse when initially treated with penicillamine. Other available anticopper drug therapies do not appear to offer a solution to this treatment problem. We are developing and evaluating a new drug, ammonium tetrathiomolybdate for this purpose. Theoretically, tetrathiomolybdate has optimal properties, including an immediate blockade of copper absorption and the property of forming complexes with copper in the blood, rendering the copper nontoxic. In this article, we present results from six patients treated with tetrathiomolybdate for up to 8 weeks as initial therapy. None of the five patients who had presented with acute neurological symptoms worsened. Also presented are methods of assay, preliminary stability studies, and methods of evaluating therapeutic end points with respect to copper metabolism.

Author Affiliations
From the Departments of Human Genetics (Drs Brewer and Yuzbasiyan-Gurkin, and Mr Dick), Internal Medicine (Dr Brewer), Pharmacy (Ms Tankanow), Neurology (Dr Young), and Speech Language Pathology (Ms Kluin), University of Michigan, Ann Arbor.

Footnotes
Accepted for publication May 22, 1990.

Reprint requests to Department of Human Genetics, University of Michigan, 4708 Medical Science II, Box 0618, Ann Arbor, MI 48109-0618 (Dr Brewer).

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati     What's this?

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Improvement in Dissolution of Liver Fibrosis in an Animal Model by Tetrathiomolybdate
Hou et al.
Exp. Biol. Med. 2009;234:662-665.
ABSTRACT | FULL TEXT  

Tetrathiomolybdate Is Partially Protective Against Hyperglycemia in Rodent Models of Diabetes
Zeng et al.
Exp. Biol. Med. 2008;233:1021-1025.
ABSTRACT | FULL TEXT  

Tetrathiomolybdate Protects against Bile Duct Ligation-Induced Cholestatic Liver Injury and Fibrosis
Song et al.
J. Pharmacol. Exp. Ther. 2008;325:409-416.
ABSTRACT | FULL TEXT  

Molecular pathogenesis of Wilson and Menkes disease: correlation of mutations with molecular defects and disease phenotypes
de Bie et al.
J. Med. Genet. 2007;44:673-688.
ABSTRACT | FULL TEXT  

Treatment of Wilson Disease With Ammonium Tetrathiomolybdate: IV. Comparison of Tetrathiomolybdate and Trientine in a Double-blind Study of Treatment of the Neurologic Presentation of Wilson Disease.
Brewer et al.
Arch Neurol 2006;63:521-527.
ABSTRACT | FULL TEXT  

The Effect of Tetrathiomolybdate on Cytokine Expression, Angiogenesis, and Tumor Growth in Squamous Cell Carcinoma of the Head and Neck
Teknos et al.
Arch Otolaryngol Head Neck Surg 2005;131:204-211.
ABSTRACT | FULL TEXT  

Effects of Tetrathiomolybdate in a Mouse Model of Retinal Neovascularization
Elner et al.
IOVS 2005;46:299-303.
ABSTRACT | FULL TEXT  

Tetrathiomolybdate Therapy Protects Against Concanavalin A and Carbon Tetrachloride Hepatic Damage in Mice
Askari et al.
Exp. Biol. Med. 2004;229:857-863.
ABSTRACT | FULL TEXT  

Inhibition of the Growth of Squamous Cell Carcinoma by Tetrathiomolybdate-Induced Copper Suppression in a Murine Model
Cox et al.
Arch Otolaryngol Head Neck Surg 2003;129:781-785.
ABSTRACT | FULL TEXT  

Phase II Trial of Tetrathiomolybdate in Patients with Advanced Kidney Cancer
Redman et al.
Clin. Cancer Res. 2003;9:1666-1672.
ABSTRACT | FULL TEXT  

Treatment of Wilson Disease With Ammonium Tetrathiomolybdate: III. Initial Therapy in a Total of 55 Neurologically Affected Patients and Follow-up With Zinc Therapy
Brewer et al.
Arch Neurol 2003;60:379-385.
ABSTRACT | FULL TEXT  

Cancer Therapy With Tetrathiomolybdate: Antiangiogenesis by Lowering Body Copper--A Review
Brewer and Merajver
Integr Cancer Ther 2002;1:327-337.
ABSTRACT  

Copper Deficiency Induced by Tetrathiomolybdate Suppresses Tumor Growth and Angiogenesis
Pan et al.
Cancer Res. 2002;62:4854-4859.
ABSTRACT | FULL TEXT  

Copper Control as an Antiangiogenic Anticancer Therapy: Lessons from Treating Wilson's Disease
Brewer
Exp. Biol. Med. 2001;226:665-673.
ABSTRACT | FULL TEXT  

Recognition, Diagnosis, and Management of Wilson's Disease
Brewer
Exp. Biol. Med. 2000;223:39-46.
ABSTRACT | FULL TEXT  

Treatment of Metastatic Cancer with Tetrathiomolybdate, an Anticopper, Antiangiogenic Agent: Phase I Study
Brewer et al.
Clin. Cancer Res. 2000;6:1-10.
ABSTRACT | FULL TEXT  

Treatment of Wilson Disease With Ammonium Tetrathiomolybdate: II. Initial Therapy in 33 Neurologically Affected Patients and Follow-up With Zinc Therapy
Brewer et al.
Arch Neurol 1996;53:1017-1025.
ABSTRACT  

Treatment of Wilson's Disease With Ammonium Tetrathiomolybdate: I. Initial Therapy in 17 Neurologically Affected Patients
Brewer et al.
Arch Neurol 1994;51:545-554.
ABSTRACT  

Molybdenum: An Essential Trace Element
Sardesai
Nutr Clin Pract 1993;8:277-281.
ABSTRACT  

Thiomolybdates in the Treatment of Wilson's Disease
Walshe
Arch Neurol 1992;49:132-132.
ABSTRACT  

Thiomolybdates in the Treatment of Wilson's Disease-Reply
Brewer
Arch Neurol 1992;49:132-133.
ABSTRACT